PURPOSE: To characterize the time-course of sleep in insomnia patients as well as placebo and concentration-effect relationships of two hypnotic compounds, PD 0200390 and zolpidem, using an accelerated model-building strategy based on mixed-effects Markov models. METHODS: Data were obtained in a phase II study with the drugs. Sleep stages were recorded during eight hours of sleep for two nights per treatment for the five treatments. First-order Markov models were developed for one transition at a time in a sequential manner; first a baseline model, followed by placebo and lastly the drug models. To accelerate the process, predefined models were selected based on a priori knowledge of sleep, including inter-subject and inter-occasion variability. RESULTS:Baseline sleep was described using piece-wise linear models, depending on time of night and duration of sleep stage. Placebo affected light sleep stages; drugs also affected slow-wave sleep. Administering PD 0200390 30 min earlier than standard dosing was shown through simulations to reduce latency to persistent sleep by 40%. CONCLUSION: The proposed accelerated model-building strategy resulted in a model well describing sleep patterns of insomnia patients with and without treatments.
RCT Entities:
PURPOSE: To characterize the time-course of sleep in insomniapatients as well as placebo and concentration-effect relationships of two hypnotic compounds, PD 0200390 and zolpidem, using an accelerated model-building strategy based on mixed-effects Markov models. METHODS: Data were obtained in a phase II study with the drugs. Sleep stages were recorded during eight hours of sleep for two nights per treatment for the five treatments. First-order Markov models were developed for one transition at a time in a sequential manner; first a baseline model, followed by placebo and lastly the drug models. To accelerate the process, predefined models were selected based on a priori knowledge of sleep, including inter-subject and inter-occasion variability. RESULTS: Baseline sleep was described using piece-wise linear models, depending on time of night and duration of sleep stage. Placebo affected light sleep stages; drugs also affected slow-wave sleep. Administering PD 0200390 30 min earlier than standard dosing was shown through simulations to reduce latency to persistent sleep by 40%. CONCLUSION: The proposed accelerated model-building strategy resulted in a model well describing sleep patterns of insomniapatients with and without treatments.
Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: M O Karlsson; R C Schoemaker; B Kemp; A F Cohen; J M van Gerven; B Tuk; C C Peck; M Danhof Journal: Clin Pharmacol Ther Date: 2000-08 Impact factor: 6.875
Authors: D J Greenblatt; J S Harmatz; L L von Moltke; B L Ehrenberg; L Harrel; K Corbett; M Counihan; J A Graf; M Darwish; P Mertzanis; P T Martin; W H Cevallos; R I Shader Journal: Clin Pharmacol Ther Date: 1998-11 Impact factor: 6.875
Authors: Chris Stockmann; Michele M Gottschlich; Daniel Healy; Jane C Khoury; Theresa Mayes; Catherine M T Sherwin; Michael G Spigarelli; Richard J Kagan Journal: J Burn Care Res Date: 2015 Jan-Feb Impact factor: 1.845
Authors: C Diack; O Ackaert; B A Ploeger; P H van der Graaf; R Gurrell; M Ivarsson; D Fairman Journal: J Pharmacokinet Pharmacodyn Date: 2011-09-10 Impact factor: 2.745
Authors: Benjamin D Yetton; Elizabeth A McDevitt; Nicola Cellini; Christian Shelton; Sara C Mednick Journal: PLoS One Date: 2018-04-11 Impact factor: 3.240